English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  53288673    在线人数 :  742
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"shao y y"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 216-240 / 396 (共16页)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2021-03-15T07:44:47Z Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy Shao Y.-Y.; Wu C.-H.; LI-CHUN LU; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:47Z Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy LI-CHUN LU; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:46Z Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; LI-CHUN LU; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:45Z Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study Li-Chun Lu;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; LI-CHUN LU; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:45Z Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma Lin H.-H.; Feng W.-C.; LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:44Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:44Z Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment Li-Chun Lu;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; LI-CHUN LU; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:43Z Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2021-03-15T07:44:43Z Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-15T07:44:42Z Solving the deficit of cancer pain management skills by education programs Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; LI-CHUN LU; Hsu C.-H.
臺大學術典藏 2021-03-15T06:27:34Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2021-03-10T05:34:17Z Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; Shao Y.-Y.; Ta-Chen Huang; Hsu C.-H.
臺大學術典藏 2021-03-09T06:46:09Z Fatal thrombocytopenia after oxaliplatin-based chemotherapy Shao Y.-Y.; RUEY-LONG HONG
臺大學術典藏 2021-03-09T06:46:08Z Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma Shao Y.-Y.;Ruey-Long Hong; Shao Y.-Y.; RUEY-LONG HONG
臺大學術典藏 2021-03-09T06:46:06Z Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; RUEY-LONG HONG; Hsu C.-H.; Chengb A.-L.
臺大學術典藏 2021-03-09T05:18:37Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:36Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:34Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:33Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:31Z Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:31Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2021-03-09T05:18:29Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2021-02-23T08:26:15Z A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma Yang S.-H.;Shao Y.-Y.;Lin C.-C.;Sung-Hsin Kuo;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; Shao Y.-Y.; Lin C.-C.; SUNG-HSIN KUO; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2021-02-19T06:52:27Z Solving the deficit of cancer pain management skills by education programs Shao Y.-Y.;Lin W.-Y.;Lin C.-P.;Lu L.-C.;Chih-Hung Hsu; Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU
臺大學術典藏 2021-02-19T06:52:27Z The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma Hung Y.-P.;Shao Y.-Y.;Hsu C.;Chih-Hung Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Lee J.-M.; Yang M.-H.; Chao Y.

显示项目 216-240 / 396 (共16页)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每页显示[10|25|50]项目